149 related articles for article (PubMed ID: 37620409)
1. Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells.
Liu M; Dong Q; Chen B; Liu K; Zhao Z; Wang Y; Zhuang S; Han H; Shi X; Jin Z; Hui Y; Gu Y
Br J Cancer; 2023 Oct; 129(8):1339-1349. PubMed ID: 37620409
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study.
Safi M; Jin C; Aldanakh A; Feng P; Qin H; Alradhi M; Zhang L; Zhang J; Adlat S; Zhao Y; Liu J
BMC Cancer; 2022 Sep; 22(1):978. PubMed ID: 36100891
[TBL] [Abstract][Full Text] [Related]
3. Identification and Validation of a Gene Signature for Lower-Grade Gliomas Based on Pyroptosis-Related Genes to Predict Survival and Response to Immune Checkpoint Inhibitors.
Lai G; Li K; Deng J; Liu H; Xie B; Zhong X
J Healthc Eng; 2022; 2022():8704127. PubMed ID: 35535221
[TBL] [Abstract][Full Text] [Related]
4. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
5. DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation.
Yan J; Wang S; Zhang J; Yuan Q; Gao X; Zhang N; Pan Y; Zhang H; Liu K; Yu J; Lu L; Liu H; Gao X; Zhao S; Zhang W; Reyila A; Qi Y; Zhang Q; Cang S; Lu Y; Pan Y; Kong Y; Nie Y
Cancer Biol Med; 2023 Dec; 21(3):252-66. PubMed ID: 38164720
[TBL] [Abstract][Full Text] [Related]
6. TIGIT
Tsakmaklis A; Farowski F; Zenner R; Lesker TR; Strowig T; Schlößer H; Lehmann J; von Bergwelt-Baildon M; Mauch C; Schlaak M; Knuever J; Schweinsberg V; Heinzerling LM; Vehreschild MJGT
BMC Cancer; 2023 Nov; 23(1):1160. PubMed ID: 38017389
[TBL] [Abstract][Full Text] [Related]
7. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
8. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
Front Immunol; 2021; 12():685370. PubMed ID: 34220837
[TBL] [Abstract][Full Text] [Related]
9. An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma.
Yan J; Wu X; Yu J; Kong Y; Cang S
Front Immunol; 2022; 13():839901. PubMed ID: 35280982
[TBL] [Abstract][Full Text] [Related]
10. Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.
Shi F; Zhang W; Yang Y; Yang Y; Zhao J; Xie M; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():721409. PubMed ID: 34795662
[TBL] [Abstract][Full Text] [Related]
11. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():798474. PubMed ID: 35087523
[TBL] [Abstract][Full Text] [Related]
12. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.
Andrieu C; McNamee N; Larkin AM; Maguire A; Menon R; Mueller-Eisert J; Horgan N; Kennedy S; Gullo G; Crown J; Walsh N
Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736346
[TBL] [Abstract][Full Text] [Related]
15. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
[TBL] [Abstract][Full Text] [Related]
16. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients.
Li C; Phoon YP; Karlinsey K; Tian YF; Thapaliya S; Thongkum A; Qu L; Matz AJ; Cameron M; Cameron C; Menoret A; Funchain P; Song JM; Diaz-Montero CM; Tamilselvan B; Golden JB; Cartwright M; Rodriguez A; Bonin C; Vella A; Zhou B; Gastman BR
J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34807232
[TBL] [Abstract][Full Text] [Related]
17. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
Front Immunol; 2021; 12():609728. PubMed ID: 34887846
[TBL] [Abstract][Full Text] [Related]
18. Determinants of Resistance to Checkpoint Inhibitors.
Tran L; Theodorescu D
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111080
[TBL] [Abstract][Full Text] [Related]
19. Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.
Patterson A; Auslander N
Nat Commun; 2022 Sep; 13(1):5151. PubMed ID: 36123351
[TBL] [Abstract][Full Text] [Related]
20. Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy.
Ratnayake G; Reinwald S; Edwards J; Wong N; Yu D; Ward R; Smith R; Haydon A; Au PM; van Zelm MC; Senthi S
Radiother Oncol; 2022 Aug; 173():299-305. PubMed ID: 35772575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
